Fig. 7: CSF3 and PGM2L1 promote TNBC progression in vivo.

A Control or PGM2L1-knockdown MDA-MB-231 cells were transplanted into nude mice, followed by PBS or CSF3 treatment. Images of tumors were harvested (n = 5 mice). B Tumor volumes were measured once 5 days beginning 3rd day after implantation (n = 5 mice). C Tumor weight was measured in each group (n = 5 mice). D The expression of PGM2L1 of xenograft tumors were examined by qRT-PCR (n = 3). E The protein level of PGM2L1 and EMT-related markers of xenograft tumors were examined by western blot. F Ki-67 and PGM2L1 in each group were tested by IHC staining. Scale bars, 100 μm. G Representative lung metastatic nodules in mice from different groups were counted (n = 5 mice). H Images of xenograft tumors of MDA-MB-231 cells mixed CAFs (n = 5 mice). I Tumor volumes were measured once 5 days beginning 10th day after implantation (n = 5 mice). J Tumor weight was measured in each group (n = 5 mice). K IHC staining of α-SMA, Ki-67, and PGM2L1 in each group (n = 5). Scale bars, 100 μm. The data are presented as the mean ± SD. ^#P < 0.05, **^,##P < 0.01, ***^,###P < 0.001.